InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
83.14
(
0.01%
)
Bitcoin
64,243.36
(
0.38%
)
Post# of 251721
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119569
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rwdm post# 213939

Thursday, 04/05/2018 10:12:13 AM

Thursday, April 05, 2018 10:12:13 AM

Post# of 251721
ABBV settles Humira-patent litigation with Samsung on terms more favorable (to ABBV) than the prior settlement with AMGN:

https://finance.yahoo.com/news/abbvie-announces-global-resolution-humira-120500818.html

Samsung Bioepis can launch its Humira FoB in the US on 6/30/23—five months later than AMGN’s launch date of 1/31/18 (#msg-134976468). I.e. AMGN effectively gained five months of Humira-FoB exclusivity in the US market by being the first to settle with ABBV.

Note: The Humira patents in question pertain to formulation and methods of use, not CoM.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up